VBI Vaccines Presents Data at the World Vaccine Congress

New Post Public Reply Private Reply Replies (0) Message Board
News Desk 2018
VBI Vaccines Presents Data at the World Vaccine Congress Asia That Supports the Potential Use of Its eVLP Platform in the Development of a Novel Hepatitis C Vaccine Candidate

CAMBRIDGE, Mass., June 3, 2015 (GLOBE NEWSWIRE) -- VBI Vaccines (Nasdaq: VBIV ) ("VBI") delivered a presentation, Enveloped Virus-Like Particles: Third-generation VLPs for the Development of a Broadly Neutralizing Hepatitis C Vaccine , today at the World Vaccine Congress Asia . The event was held in Singapore at the Suntec Singapore Convention & Exhibition Centre.

A synopsis of the presentation, which was delivered by Jeff Baxter, VBI's President and CEO, is available here: http://www.vbivaccines.com/wire/wvc-asia-2015

VBI's Hepatitis C ("HCV") vaccine candidate leverages the company's eVLP vaccine platform , which enables the development of enveloped ("e") virus-like particle ("VLP") vaccines. eVLPs are an innovative new class of synthetic vaccines that are designed to closely resemble the structure of viruses. Because of their structural similarity to viruses found in nature, eVLPs are capable of imparting greater immunity than immunization with the same recombinant target protein alone.

VBI's eVLP vaccine platform has been used to develop a Hepatitis C vaccine candidate that may be capable of eliciting broadly reactive neutralizing antibodies against multiple genotypes of HCV. This is a critical issue for HCV, as the virus is characterized by multiple, geographically distinct genotypes. Addressing the genetic diversity of the Hepatitis C virus may provide an advantage in developing successful antiviral regimens or therapeutic vaccines. In addition, VBI believes its HCV vaccine candidate may be capable of replacing interferon when used in combination with standard antivirals.

"VBI has previously demonstrated strong cross-reactive neutralizing antibody responses against multiple genotypes of HCV in monkeys," said Mr. Baxter. "Based on this data, we believe our HCV vaccine candidate has the potential to be a promising and safe component of HCV treatment regimens, especially in areas where the transmission of Hepatitis C has not yet been adequately addressed by the existing field of approved and available drugs."

Now in its eighth year, the World Vaccine Congress Asia is attended by decision makers from across the Asia Pacific region including leading research institutions, government regulators, and life sciences companies. To learn more, visit: http://bit.ly/wvc-asia-2015

About VBI Vaccines Inc.

VBI Vaccines Inc. ("VBI") is a biopharmaceutical company developing novel technologies that seek to expand vaccine protection in large underserved markets. VBI's eVLP vaccine platform allows for the design of enveloped ("e") virus-like particle ("VLP") vaccines that closely mimic the target virus. VBI's lead eVLP asset is a prophylactic Cytomegalovirus ("CMV") vaccine; VBI has initiated work for GMP manufacturing of its CMV candidate for use in formal preclinical and Phase I trials. VBI's second platform is a thermostable technology that enables the development of vaccines and biologics that can withstand storage or shipment at constantly fluctuating temperatures. VBI has completed proof of concept thermostability studies on a number of vaccine and biologic targets. VBI is headquartered in Cambridge, MA with research facilities in Ottawa, Canada.

Website Home: http://www.vbivaccines.com /

News and Insights: http://www.vbivaccines.com/wire /

Investors: http://ir.vbivaccines.com /

Forward-Looking Statement Disclosure

This press release contains certain "forward-looking statements" within the meaning of the Private Securities Litigation Reform Act of 1995, as amended, including statements regarding the efficacy of potential products, the timelines for bringing such products to market, and the availability of funding sources for continued development of such products. Forward-looking statements are based on management's estimates, assumptions, and projections, and are subject to uncertainties, many of which are beyond the control of VBI. Actual results may differ materially from those anticipated in any forward-looking statement. Factors that may cause such differences include the risks that potential products that appear promising to VBI cannot be shown to be efficacious or safe in subsequent preclinical or clinical trials, VBI will not obtain appropriate or necessary governmental approvals to market these or other potential products, VBI may not be able to obtain anticipated funding for its development projects or other needed funding, and VBI may not be able to secure or enforce adequate legal protection, including patent protection, for its products. All forward-looking statements included in this press release are made only as of the date of this press release, and VBI does not undertake any obligation to publicly update or correct any forward-looking statements to reflect events or circumstances that subsequently occur or of which we hereafter become aware.

More detailed information about VBI and risk factors that may affect the realization of forward-looking statements, including the forward-looking statements in this press release, is set forth in VBI's filings with the Securities and Exchange Commission (the "Commission"). VBI urges investors and security holders to read those documents free of charge at the Commission's Web site at http://www.sec.gov . Interested parties may also obtain those documents free of charge from VBI. Forward-looking statements speak only as to the date they are made, and except for any obligation under the U.S. federal securities laws, VBI undertakes no obligation to publicly update any forward-looking statement as a result of new information, future events or otherwise.

Company Contact Perri Maduri, Communications Executive Phone: (617) 830-3031 x124 Email: Investor Contacts Robert B. Prag, President The Del Mar Consulting Group, Inc. Phone: (858) 361-1786 Email: Scott Wilfong, President Alex Partners, LLC Phone: (425) 242-0891 Email:

Scroll down for more posts ▼

Top 10 Most Recent News Articles

Newegg’s GIGABYTE Event Is Brand Work, Not a Catalyst

Updated Category News Views 261

A 2,300-square-foot room can tell a retailer plenty about its tribe. On November 21, Newegg is turning its Diamond Bar Gamer Zone into the home base for GIGABYTE’s AORUS VS40 celebration, a free five-hour event marking the hardware maker’s 40th anniversary. There will be 1v1 VALORANT and League of Legends contests, demo stations, raffles, anniversary merchandise, food...

Continue Reading
Persistent Dry Eye Symptoms Call for a Closer Look

Updated Category News Views 125

Eyes can turn into a stubborn little nuisance long before people realize something more complicated is going on. A bottle of artificial tears is easy to grab, cheap enough, and often perfectly sensible for a rough day of screens, wind, reading, or air conditioning. But Dr. Harlan Snyder’s point is the one worth sitting with: when dryness keeps barging back despite...

Continue Reading
D-Wave Investors Face a December 15 Lead Plaintiff Clock

Updated Category News Views 191

August Put the Story Under a Harsh Light Two ugly August trading sessions are doing a lot of work in the case now confronting D-Wave Quantum. The company sits in a field that attracts big dreams, big headlines, and, frankly, plenty of investor imagination. But imagination does not cushion a portfolio when expectations crack. The lawsuits concern people who bought or...

Continue Reading
Cottage Grove Tests Holiday Demand Across Lake Norman

Updated Category News Views 210

Flour and foot traffic make a pretty honest little scoreboard. Cottage Grove Bakery is putting itself in front of Lake Norman shoppers twice on Saturday, November 21, while also taking Thanksgiving orders and laying groundwork for 2027 workplace and school visits. This is not a public-company earnings story, and nobody should pretend a tray of scones is a quarterly...

Continue Reading
Alibaba Lawsuit Deadline Puts Disclosure Risk in Focus

Updated Category News Views 191

A calendar deadline is doing more work than any earnings headline for Alibaba shareholders this week. A securities class action notice says investors who bought or acquired Alibaba Group Holding Limited securities between May 23, 2024 and November 11, 2026 may seek appointment as lead plaintiff by January 19, 2027. That is a procedural milestone, not a verdict, and...

Continue Reading
Ajman Memory Gives Heritage a Durable Digital Backbone

Updated Category News Views 99

Archives usually get applause only after somebody realizes a piece of history has vanished. Ajman is trying to skip that miserable part. During the Ajman Media Forum 2026, held November 18 and 19 at the Emirates Hospitality Centre, the emirate launched Ajman Memory, a project built to collect, document and preserve photographs, papers and video recording its development....

Continue Reading
Fluence Investors Face a November 27 Litigation Clock

Updated Category News Views 187

Six calendar squares are all that separate eligible Fluence investors from the November 27, 2026 lead-plaintiff deadline. That is not much time to locate trade confirmations, calculate losses, and decide whether taking a larger role in a securities case makes sense. The lawsuit is not a verdict, and anybody pretending otherwise is selling smoke. But the underlying...

Continue Reading
Kinross Lawsuit Puts Round Mountain Claims Under Fire

Updated Category News Views 128

A mine can swallow a rosy forecast faster than any spreadsheet admits. That is the ugly center of the proposed securities class action involving Kinross Gold: not merely that production guidance came down, but the allegation that investors were sold too much confidence before the operational reality at Round Mountain Phase S surfaced. NYSE:KGC dropped from $27.62 on...

Continue Reading
Sitting, Lymph Flow, and a Supplement Maker's Pitch

Updated Category News Views 161

By late afternoon, a chair can feel like it has quietly won the argument against your legs. PureHealth Research is leaning into that familiar heavy, puffy-legged feeling with a reminder about lymphatic flow—and, naturally, an eight-ingredient supplement positioned alongside it. The broad message is sensible. The sales layer needs the usual healthy squint. Movement Does...

Continue Reading
3TREES Tests a Bigger Asia-Pacific Growth Blueprint

Updated Category News Views 211

A bucket of paint rarely sounds strategic until it sits inside a regional supply chain. That is the useful part of 3TREES chairman and president Hong Jie's message from the Asia-Pacific Economic Cooperation CEO Summit in Shenzhen on November 17-18, 2026: coatings are not merely a commodity if the supplier can bring materials, energy savings, technical know-how and...

Continue Reading

Top 5 Most Recently Viewed Articles

Marqeta Class Action Lawsuit: Investor Rights Alert

Updated Category News Views 115

Investors Take Action: Marqeta, Inc. Securities Lawsuit In an important update for shareholders of Marqeta, Inc. (NASDAQ: MQ), it has been brought to attention by Kahn Swick & Foti, LLC that investors who have incurred losses exceeding $100,000 have until a specific deadline to file lead plaintiff applications in a key class action lawsuit. Understanding the Class Action...

Continue Reading
Emerging Strategies for the Chronic Refractory Cough Market

Updated Category News Views 266

Chronic Refractory Cough Market Overview The chronic refractory cough market is emerging as a significant opportunity for pharmaceutical companies. As analyzed, the market size is poised for considerable growth due to various factors, including rising disease prevalence and a corresponding increase in approved product availability. Notably, several innovative therapies...

Continue Reading
Hydreight Technologies: A Rising Star in Healthcare Services

Updated Category News Views 185

Hydreight Technologies Achieves Major Recognition In the fast-paced world of technology and healthcare, Hydreight Technologies Inc. has made an impressive mark, securing the spot of No. 77 on a prestigious list of the fastest-growing companies in North America. This ranking, part of the 2025 Deloitte Technology Fast 500™, positions Hydreight among elite innovators and...

Continue Reading
Empowering Communities: PHFA's $75 Million Housing RFP Launch

Updated Category News Views 90

Introducing the New PHARE Funding Opportunities for Housing The Pennsylvania Housing Finance Agency (PHFA) is excited to announce a new funding opportunity that aims to improve housing availability and affordability across the state. This initiative encourages organizations to submit proposals for projects designed to address urgent housing challenges in their...

Continue Reading
Investigating Investor Claims Against Polestar Automotive

Updated Category News Views 114

Investigation of Investor Claims Against Polestar Automotive Faruqi & Faruqi, LLP, a prominent national securities law firm, is initiating an investigation into potential claims for investors of Polestar Automotive Holding UK PLC. If you've experienced financial losses linked to Polestar, now is the time to explore your options and safeguard your rights. Understanding...

Continue Reading